High-throughput screening for the identification of small-molecule inhibitors of retinoblastoma protein phosphorylation in cells

Analytical Biochemistry

Volumn 320, Issue 1, 2003, Pages 66-74

  Barrie, S Elaine ^a   Eno Amooquaye, Ebun ^a   Hardcastle, Anthea ^a   Platt, Georgina ^a   Richards, Juliet ^a   Bedford, David ^a   Workman, Paul ^a   Aherne, Wynne ^a   Mittnacht, Sibylle ^a   Garrett, Michelle D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer; CDK; Inhibitors; Phosphorylation; Retinoblastoma protein; Screen

Indexed keywords

AMINO ACIDS; CELLS; CHEMICAL DETECTION; CORROSION INHIBITORS; CYTOLOGY; DIAGNOSIS; DISEASES; ENZYMES; MOLECULES; MONOCLONAL ANTIBODIES; SCREENING; SIGNAL DETECTION; TUMORS;

CANCER; CYCLIN-DEPENDENT KINASE; HIGH THROUGHPUT SCREENING; HIGH-THROUGHPUT ASSAYS; RETINOBLASTOMA PROTEIN; SMALL MOLECULE INHIBITOR; TIME-RESOLVED FLUORESCENCE; TUMOR SUPPRESSOR PROTEINS;

PHOSPHORYLATION;

CYCLIN DEPENDENT KINASE; CYCLINE; EUROPIUM; MONOCLONAL ANTIBODY; RETINOBLASTOMA PROTEIN; SERINE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; FLUORESCENCE; HUMAN; HUMAN CELL; IMMUNOADSORBENT; MOLECULE; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; SCREENING; SIGNAL DETECTION;

EID: 10744229250     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-2697(03)00349-X     Document Type: Article

References (23)

1. Hinds P.W., Weinberg R.A. Tumor suppressor genes. Curr. Opin. Genet. Dev. 4:1994;135-141.
2. Friend S.H., Bernards R., Rogelj S., Weinberg R.A., Rapaport J.M., Albert D.M., Dryja T.P. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (London). 323:1986;643-646.
3. Harbour J.W., Dean D.C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 1:2000;2393-2409.
4. Tamrakar S., Rubin E., Ludlow J.W. Role of pRB dephosphorylation in cell cycle regulation. Front. Biosci. 5:2000;121-137.
5. Mittnacht S. Control of pRB phosphorylation. Curr. Opin. Genet. Dev. 8:1998;21-27.
6. Rubin E., Mittnacht S., Villa-Moruzzi E., Ludlow J.W. Site-specific and temporally regulated retinoblastoma protein dephosphorylation by protein phosphatase type 1. Oncogene. 20:2001;3776-3785.
7. Harbour J.W., Luo R.X., Dei Santi A., Postigo A.A., Dean D.C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 98:1999;859-869.
8. Morgan D.O. Principles of CDK regulation. Nature (London). 374:1995;131-134.
9. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1999;1501-1512.
10. Taipale J., Beachy P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature (London). 411:2001;349-354.
11. Pruitt K., Der C.J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 171:2001;1-10.
12. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68:1996;67-108.
13. Moberg K.H., Bell D.W., Wahrer D.C., Haber D.A., Hariharan I.K. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature (London). 413:2001;311-316.
14. Strohmaier H., Spruck C.H., Kaiser P., Won K.A., Sangfelt O., Reed S.I. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature (London). 413:2001;316-322.
15. Workman P., Kaye S.B. Translating basic cancer research into new cancer therapeutics. Trends Mol. Med. 8:2002;S1-S9.
16. Workman P. Scoring a bull's-eye against cancer genome targets. Curr. Opin. Pharmacol. 1(4):2001;342-352.
17. Harlow E., Lane D. Antibodies: A Laboratory Manual. 1988;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
18. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;1107-1112.
19. Fry D.W., Bedford D.C., Harvey P.H., Fritsch A., Keller P.R., Wu Z., Dobrusin E., Leopold W.R., Fattaey A., Garrett M.D. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J. Biol. Chem. 276:2001;16617-16623.
20. Zarkowska T., Harlow E., Mittnacht S. Monoclonal antibodies specific for underphosphorylated retinoblastoma protein identify a cell cycle regulated phosphorylation site targeted by CDKs. Oncogene. 14:1997;249-254.
21. Alessi F., Quarta S., Savio M., Riva F., Rossi L., Stivala L.A., Scovassi A.I., Meijer L., Prosperi E. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in phase by specific inhibition of CDK2 kinase activity. Exp. Cell Res. 245:1998;8-18.
22. Peruski A.H., Johnson III L.H., Peruski L.F. Jr. Rapid and sensitive detection of biological warfare agents using time-resolved fluorescence assays. J. Immunol. Methods. 263:2002;35-41.
23. Smith D.R., Rossi C.A., Kijek T.M., Henchal E.A., Ludwig G.V. Comparison of dissociation-enhanced lanthanide fluorescent immunoassays to enzyme-linked immunosorbent assays for detection of staphylococcal enterotoxin B, Yersinia pestis-specific F1 antigen, and Venezuelan equine encephalitis virus. Clin. Diagn. Lab. Immunol. 8:2001;1070-1075.